Table 1.
Patient demographic characteristics
| n (%) | ||
| Sex | Male | 6 (25.0) |
| Female | 18 (75.0) | |
| Age | Mean (range) | 61.2 ± 11.5 (39-86) |
| Primary tumor | Breast | 11 (45.8) |
| Gynecological | 4 (16.7) | |
| Hematological | 3 (12.5) | |
| Gastrointestinal | 3 (12.5) | |
| Others | 3 (12.5) | |
| Responsible chemotherapeutic agents (overlapping, see Table 4) | Taxanes | 15 (62.5) |
| Platinum analogues | 7 (29.2) | |
| Vinca alkaloids | 3 (12.5) | |
| Bortezomiib | 3 (12.5) | |
| Duration until starting Kampo medicine after responsible chemotherapy | During chemotherapy | 6 (25.0) |
| < 6 mo after | 8 (33.3) | |
| 7-12 mo after | 4 (16.7) | |
| > 13 mo after | 6 (25.0) | |